- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05024175
Langzeit-Follow-up von Patienten, die mit CARv3-TEAM-E-T-Zellen behandelt wurden
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a long-term safety and efficacy follow-up study for subjects who have been treated with CAR T cells in corresponding Phase I main studies that evaluated the safety and efficacy of CAR T cells in subjects.
No investigational treatment will be administered in this study.
The FDA (2020) recommends long-term follow up for subjects treated with gene therapy drug products to monitor for delayed adverse events (AEs), as well as durability of clinical response.
Therefore, after monitoring of subjects in the main studies has been completed (24 months after CAR T cells infusion, or <24 months after CAR T cells infusion if subject terminated early due to disease progression or due to discontinuing corresponding main study for any reason), subjects will be asked to participate in a long-term follow-up study (LTFU).
Subjects will be followed for up to 15 years following their last CAR T cells infusion in the corresponding main study.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Matthew J Frigault, MD
- Telefonnummer: 617-643-6175
- E-Mail: mfrigault@mgb.org
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Rekrutierung
- Massachusetts General Hospital
-
Hauptermittler:
- Matthew J Frigault, MD
-
Kontakt:
- Matthew J Frigault, MD
- Telefonnummer: (617) 724-4000
- E-Mail: mfrigault@mgb.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit
Beschreibung
Inclusion Criteria:
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.
Subjects meeting the following criteria are eligible for study participation:
- Provision of voluntary written informed consent by subject
- CAR T cells were administered in HCC IRB or MGB IRB corresponding main study
Exclusion Criteria:
Subjects meeting the following criterion are to be excluded from study participation:
- Subject unable to comply with study requirements
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
CAR T cells
|
CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol Tumor Biopsy per protocol Blood Test per protocol |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival
Zeitfenster: 1 month
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
1 month
|
|
Overall Survival
Zeitfenster: 6 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
6 months
|
|
Overall Survival
Zeitfenster: 12 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
12 months
|
|
Overall Survival
Zeitfenster: 24 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
24 months
|
|
Progresison Free Survival
Zeitfenster: 1 month
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
1 month
|
|
Progresison Free Survival
Zeitfenster: 6 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
6 months
|
|
Progresison Free Survival
Zeitfenster: 12 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
12 months
|
|
Progresison Free Survival
Zeitfenster: 24 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
24 months
|
|
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
Zeitfenster: Up to 15 Years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
Up to 15 Years
|
|
New incidence of a hematologic disorder
Zeitfenster: up to 15 years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
up to 15 years
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
Zeitfenster: up to 15 years
|
NCI Common Terminology Criteria for Adverse Events (CTCAE) |
up to 15 years
|
|
Vector-derived RCL
Zeitfenster: baseline and in 3 months, 6 months, and annually up to 15 years
|
Archiving of samples for potential detection of vector-derived RCL. RCL testing will be monitored at the central RCL lab (Indiana University) by a suitable qPCR assay for detection of the lentiviral vector (VSV-g DNA). |
baseline and in 3 months, 6 months, and annually up to 15 years
|
|
Assessment of CAR T cells persistence by VCN in peripheral blood
Zeitfenster: baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
VCN will be performed in DNA from whole blood to monitor for persistence of vector sequence |
baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
|
Progression-free Survival
Zeitfenster: From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
The number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
|
Overall Survival
Zeitfenster: From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
The time from post-CAR T cells infusion to the date of death. |
From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Matthew J Frigault, MD, Massachusetts General Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20-721
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The Harvard Cancer Consortium (HCC) encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-Sharing-Zeitrahmen
Data can be shared no earlier than 1 year following the date of publication
IPD-Sharing-Zugriffskriterien
Contact the Partners Innovations team at http://www.partners.org/innovation
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .